InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Update on Regulatory Approval Process for Dupuytren’s Disease Treatment

180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that it has submitted a request to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for a follow-up scientific advice meeting where the company will seek guidance on a plan to obtain Conditional Marketing Authorization (“CMA”) for the use of adalimumab in the treatment of early stage Dupuytren’s disease. The meeting is anticipated to take place in the late third quarter, with written responses anticipated to be received prior to year-end 2023. According to the company’s regulatory consultants, an additional clinical trial (phase 3) may be required to obtain CMA approval, and such a trial has been designed. ATNF’s regulatory consultants believe obtaining of a CMA may be possible due to the long safety history of anti-tumor necrosis factor (“TNF”) therapies, conditional on a successful phase 3 trial, which, upon patient enrollment, the CMA may be granted prior to completion and based on the company’s commitment to complete the phase 3 trial.

To view the full press release, visit https://ibn.fm/tEnly

About 180 Life Sciences Corp.

180 Life Sciences is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.